The estimated Net Worth of Karen C Lam is at least $140 millier dollars as of 2 November 2020. Karen Lam owns over 2,022 units of RAPT Therapeutics stock worth over $24,579 and over the last 5 years Karen sold RAPT stock worth over $115,721.
Karen has made over 4 trades of the RAPT Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Karen sold 2,022 units of RAPT stock worth $56,899 on 2 November 2020.
The largest trade Karen's ever made was exercising 2,777 units of RAPT Therapeutics stock on 12 May 2020 worth over $5,165. On average, Karen trades about 1,251 units every 30 days since 2020. As of 2 November 2020 Karen still owns at least 12,735 units of RAPT Therapeutics stock.
You can see the complete history of Karen Lam stock trades at the bottom of the page.
Karen's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel et Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics executives and other stock owners filed with the SEC include: